These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 15982595)

  • 1. The association of elevated creatine kinase-myocardial band on mortality after coronary artery bypass grafting surgery is time and magnitude limited.
    Engoren MC; Habib RH; Zacharias A; Schwann TA; Riordan CJ; Durham SJ; Shah A
    Eur J Cardiothorac Surg; 2005 Jul; 28(1):114-9. PubMed ID: 15982595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased creatine kinase MB level predicts postoperative mortality after cardiac surgery independent of new Q waves.
    Ramsay J; Shernan S; Fitch J; Finnegan P; Todaro T; Filloon T; Nussmeier NA
    J Thorac Cardiovasc Surg; 2005 Feb; 129(2):300-6. PubMed ID: 15678039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reoperative coronary artery bypass grafting: analysis of early and late outcomes.
    Di Mauro M; Iacò AL; Contini M; Teodori G; Vitolla G; Pano M; Di Giammarco G; Calafiore AM
    Ann Thorac Surg; 2005 Jan; 79(1):81-7. PubMed ID: 15620920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cardiac troponin I versus T and creatine kinase MB after coronary artery bypass grafting in patients with and without perioperative myocardial infarction.
    Peivandi AA; Dahm M; Opfermann UT; Peetz D; Doerr F; Loos A; Oelert H
    Herz; 2004 Nov; 29(7):658-64. PubMed ID: 15580320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative white blood cell count is independently associated with higher perioperative cardiac enzyme release and increased 1-year mortality after coronary artery bypass grafting.
    Newall N; Grayson AD; Oo AY; Palmer ND; Dihmis WC; Rashid A; Stables RH
    Ann Thorac Surg; 2006 Feb; 81(2):583-9. PubMed ID: 16427856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study.
    Tardif JC; Carrier M; Kandzari DE; Emery R; Cote R; Heinonen T; Zettler M; Hasselblad V; Guertin MC; Harrington RA;
    J Thorac Cardiovasc Surg; 2007 Jun; 133(6):1604-11. PubMed ID: 17532963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery.
    Carrier M; Ménasché P; Levy JH; Newman MF; Taylor KM; Haverich A; Chen JC; Shernan SK; Van de Werf F; van der Laan M; Todaro TG; Adams PX; Verrier ED
    J Thorac Cardiovasc Surg; 2006 Feb; 131(2):352-6. PubMed ID: 16434264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk and determinants of myocardial injury during off-pump coronary artery bypass grafting.
    Nathoe HM; Moons KG; van Dijk D; Jansen EW; Borst C; de Jaegere PP; Grobbee DE;
    Am J Cardiol; 2006 May; 97(10):1482-6. PubMed ID: 16679088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical assessment of myocardial injury after cardiac surgery: effects of a platelet activating factor antagonist, bilateral internal thoracic artery grafts, and coronary endarterectomy.
    Taggart DP
    J Thorac Cardiovasc Surg; 2000 Oct; 120(4):651-9. PubMed ID: 11003744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.
    Shernan SK; Fitch JC; Nussmeier NA; Chen JC; Rollins SA; Mojcik CF; Malloy KJ; Todaro TG; Filloon T; Boyce SW; Gangahar DM; Goldberg M; Saidman LJ; Mangano DT;
    Ann Thorac Surg; 2004 Mar; 77(3):942-9; discussion 949-50. PubMed ID: 14992903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocardial injury in coronary artery bypass grafting: on-pump versus off-pump comparison by measuring high-sensitivity C-reactive protein, cardiac troponin I, heart-type fatty acid-binding protein, creatine kinase-MB, and myoglobin release.
    Chowdhury UK; Malik V; Yadav R; Seth S; Ramakrishnan L; Kalaivani M; Reddy SM; Subramaniam GK; Govindappa R; Kakani M
    J Thorac Cardiovasc Surg; 2008 May; 135(5):1110-9, 1119.e1-10. PubMed ID: 18455592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of avoiding cardiopulmonary bypass for coronary surgery on perioperative cardiac enzyme release and survival.
    Kuduvalli M; Newall N; Stott A; Grayson AD; Fabri BM
    Eur J Cardiothorac Surg; 2006 May; 29(5):729-35. PubMed ID: 16520048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal timing of coronary artery bypass after acute myocardial infarction: a review of California discharge data.
    Weiss ES; Chang DD; Joyce DL; Nwakanma LU; Yuh DD
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):503-11, 511.e1-3. PubMed ID: 18329460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic significance of the elevation of the indices of myocardial damage after percutaneous coronary revascularization interventions].
    Cavallini C; Savonitto S
    Ital Heart J Suppl; 2002 Mar; 3(3):286-96. PubMed ID: 12040844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On-pump versus off-pump coronary artery bypass grafting: more heat-shock protein 70 is released after on-pump surgery.
    Dybdahl B; Wahba A; Haaverstad R; Kirkeby-Garstad I; Kierulf P; Espevik T; Sundan A
    Eur J Cardiothorac Surg; 2004 Jun; 25(6):985-92. PubMed ID: 15144999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk of heart failure as a consequence of perioperative myocardial injury after coronary artery bypass grafting.
    Steuer J; Granath F; de Faire U; Ekbom A; Ståhle E
    Heart; 2005 Jun; 91(6):754-8. PubMed ID: 15894769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic discrimination between graft-related and non-graft-related perioperative myocardial infarction with cardiac troponin I after coronary artery bypass surgery.
    Thielmann M; Massoudy P; Schmermund A; Neuhäuser M; Marggraf G; Kamler M; Herold U; Aleksic I; Mann K; Haude M; Heusch G; Erbel R; Jakob H
    Eur Heart J; 2005 Nov; 26(22):2440-7. PubMed ID: 16087649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery.
    Collard CD; Body SC; Shernan SK; Wang S; Mangano DT; ;
    J Thorac Cardiovasc Surg; 2006 Aug; 132(2):392-400. PubMed ID: 16872968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time.
    Smith PK; Carrier M; Chen JC; Haverich A; Levy JH; Menasché P; Shernan SK; Van de Werf F; Adams PX; Todaro TG; Verrier E
    Ann Thorac Surg; 2006 Sep; 82(3):781-8; discussion 788-9. PubMed ID: 16928483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A three-group model to predict mortality in emergent coronary artery bypass graft surgery.
    Danner BC; Didilis VN; Stojanovic T; Popov A; Grossmann M; Seipelt R; Schöndube FA
    Ann Thorac Surg; 2009 Nov; 88(5):1433-9. PubMed ID: 19853087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.